Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetuximab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Merck KGaA
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + paclitaxel is a combination regimen used primarily in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN), especially in patients who are ineligible for platinum-based chemotherapy or have progressed after such regimens. Cetuximab is a monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR), blocking downstream signaling pathways involved in tumor cell proliferation, survival, motility, and invasion. Paclitaxel is a small molecule chemotherapeutic agent that stabilizes microtubules, thereby inhibiting mitosis and inducing apoptosis in rapidly dividing cells. The combination has shown efficacy as both first-line therapy for unfit patients and as second-line therapy following progression on platinum-based treatments[1][5][6][8].
- Brand names
- ErbituxTaxol
- Other names
- None
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on Cetuximab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cetuximab + paclitaxel.